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Chronic HBV (CHB) infection suppresses virus-specific T cells, but its impact on humoral
immunity has been poorly analyzed. Here, we developed a dual-staining method that
utilizes hepatitis B virus (HBV) surface antigens (HBsAg) labeled with fluorochromes as
“baits” for specific ex vivo detection of HBsAg-specific B cells and analysis of their quantity,
function, and phenotype. We studied healthy vaccinated subjects (n = 18) and patients with
resolved (n = 21), acute (n = 11), or chronic (n = 96) HBV infection and observed that
frequencies of circulating HBsAg-specific B cells were independent of HBV infection status.
In contrast, the presence of serum HBsAg affected function and phenotype of HBsAg-
specific B cells that were unable to mature in vitro into Ab-secreting cells and displayed an
increased expression of markers linked to hyperactivation (CD21lo) and exhaustion (PD-1).
Importantly, B cell alterations were not limited to HBsAg-specific B cells, but affected the
global B cell population. HBsAg-specific B cell maturation could be partially restored by a
method involving the combination of the cytokines IL-2 and IL-21 and CD40L-expressing
feeder cells and was further boosted by the addition of anti–PD-1 Abs. In conclusion, HBV
infection has a marked impact on global and HBV-specific humoral immunity, yet HBsAg-
specific B cells are amenable to a partial rescue by B cell–maturing cytokines and PD-1
blockade.
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Introduction
The coordinated activation of different components of the 
immune system is crucial for protection from pathogens. While 
innate immunity controls the initial response to infection, spe-
cific humoral and cellular immunity are required to eliminate 
the pathogen and prevent reinfection. The progressive functional 
inactivation of adaptive immunity characterizes persistent infec-
tions with alterations in both global and antigen-specific T and B 
cell compartments (1–5).
A similar situation is evident during hepatitis B virus (HBV) 
infection in which virus control is associated with the presence of 
functional antiviral T cells and with the serological detection of 
anti–HBV surface (anti-HBs) Abs (6). However, while the quantity 
and function of HBV-specific T cells have been clearly defined in 
chronic HBV (CHB) patients (7–12), detailed characterization of 
the anti-HBV–specific B cell response is lacking. In order to fill this 
knowledge gap, we developed a system that utilizes recombinant 
HBV surface antigens (HBsAg) labeled with 2 different fluoro-
chromes for ex vivo detection of HBsAg-specific B cells by flow 
cytometry. This method is independent of the secretory function 
of Abs and allows precise measurement of the frequency and func-
tion of HBsAg-specific B cells.
Studies in CHB patients have reported activation (13) and 
reduced functional capacity (14) of the global B cell population and 
have typically been unable to detect anti-HBs–secreting B cells 
(15–17), which have been suggested as being deleted by HBsAg- 
specific CD8+ T cells (18). However, the presence of HBsAg/anti-
HBs immune complexes in the sera of CHB patients (19) and detec-
tion of rare anti-HBs Abs–producing cells in ELISpot assays per-
formed on peripheral blood mononuclear cells (PBMCs) of CHB 
patients (14, 20) suggest that deletion or functional inactivation 
of HBsAg-specific B cells is not complete (21). The current study 
focused on HBsAg-specific B cells because, even though humoral 
responses target all HBV proteins (19), only anti-HBs–specific Abs 
are associated with the concept of functional HBV cure (serologi-
cal negativity of HBV DNA and HBsAg) and protection (22, 23). 
Anti-HBs Abs target different epitopes located in the small surface 
protein of HBV (24) and exhibit a protective role by blocking the 
interaction of HBV with heparan sulfate molecules (25), but addi-
tional mechanisms, such as direct suppression of HBV production 
from infected hepatocytes (26, 27), have been suggested.
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worked successfully. We stained PBMCs isolated from this sub-
ject with DyLight 550– and DyLight 650–labeled HBsAg (HBsAg-
D550 and HBsAg-D650) and Abs that allowed gating on total 
memory B cells (MBCs) (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI121957DS1). Figure 1, D and E, shows the frequency of double-
positive HBsAg-D550+D650+ MBCs (naive CD21+CD27– exclud-
ed) within the total CD19+ B cell population from the day of boost 
(day 0) to day 60 after HBV vaccination.
In parallel with the kinetics of total plasmablasts and Ab pro-
duction, the frequency of double-positive HBsAg-D550+/650+ 
MBCs peaked at day 7, reaching 0.4% of total CD19+ B cells (Fig-
ure 1E), and then gradually declined. This HBsAg double-positive 
B cell population principally comprised CD27hiCD38hi plasma-
blasts at day 7 to 9 after vaccination, while HBsAg-D550+/650+ 
plasmablasts were not detectable 15 days after booster vaccination 
(Figure 1D). Interestingly, the mean fluorescence intensity (MFI) 
of HBsAg-D550+/650+ double-positive B cells increased progres-
sively over time (Figure 1F), as expected from MBCs that express 
higher levels of surface BCR than plasmablasts. Finally, no chang-
es in the frequency of HBsAg-D550+/650+ B cells were detected 
on naive (CD21+CD27–) B cells (Supplemental Figure 1). These 
data suggest that our fluorochrome-conjugated HBsAg is able to 
directly detect ex vivo HBsAg-specific B cells.
To confirm this, HBsAg-D550+/650+ and HBsAg-D550–/650– 
MBCs were sorted and cultured in vitro after polyclonal stimula-
tion to induce expansion, plasmablast differentiation, and Ab 
production. Only HBsAg-D550+/650+ B cells secreted anti-HBs 
Abs, as measured by ELISA and ELISpot assays (Figure 1G). Thus, 
HBsAg-D550 and HBsAg-D650 can identify HBsAg-specific B 
cells directly ex vivo at a single-cell level.
Frequency of HBsAg-specific B cells during HBV infection. We first 
utilized HBsAg-D550 and HBsAg-D650 to measure the frequency 
of HBsAg-specific B cells in the peripheral blood of HBV-vaccinat-
ed subjects and patients acutely or chronically infected with HBV. 
The clinical and virological profiles of the tested subjects are sum-
marized in Table 1. We studied 18 healthy vaccinated subjects, 11 
acute (HBsAg+, IgM anti-core+, high ALT), and 21 resolved (anti-
An unusual feature of the HBV replication cycle is that virus-
infected hepatocytes secrete a large quantity of subviral particles 
(HBsAg) in addition to infectious virions. These noninfectious 
subviral particles vastly outnumber HBV virions in the circula-
tion of CHB patients (by 103- to 106-fold) and can reach concen-
trations as high as 50 to 100 μg/ml (24). Importantly, the small 
S HBV protein is present in both viral and subviral particles, and 
thus, anti-HBs Abs target both HBV virions and HBsAg. The evolu-
tionary reason that HBV has developed its ability to produce large 
quantities of subviral, noninfectious particles is still not clear. One 
attractive hypothesis is that HBsAg functions as a decoy to satu-
rate anti-HBs Abs and so prevents virus neutralization (28). It has 
also been proposed that HBsAg can suppress innate, humoral, or 
cellular immunity (29). In this study, we developed a method to 
directly detect HBsAg-specific B cells ex vivo, which allows us to 
analyze the impact that HBsAg has on the quantity, phenotype, 
and function of virus-specific B cells and on potential strategies 
that can boost their functionality.
Results
Direct ex vivo detection of HBsAg-specific B cells. Direct visualization 
of HBsAg-specific B cells utilizing HBsAg-conjugated microbeads 
has been performed in HBsAg-vaccinated individuals (30), but 
not in patients with HBV infection in whom anti–HBV-specific B 
cells have so far been evaluated using functional assays that might 
underestimate their size (15–17). In order to detect low-frequency 
antigen-specific B cells (31), 2 batches of HBsAg (genotype A) were 
chemically labeled with 2 distinct fluorochromes, DyLight 550 
and DyLight 650 (Figure 1A). The fluorochrome-labeled HBsAg 
reagents were designed to act as “bait” to bind specifically to anti-
HBsAg B cell receptors (BCRs) on the cell surface of CD19+ B cells.
To test this strategy, we evaluated peripheral blood samples 
from a healthy subject who received an HBV vaccine boost. Serum 
levels of IgG anti-HBs following the booster vaccination increased 
by day 7 and remained high until day 60 (Figure 1B). In addi-
tion, the frequency of total plasmablasts in the peripheral blood 
of this vaccinated subject reached maximum levels on day 7 after 
vaccination (Figure 1C), confirming that the booster vaccination 
Table 1. Details of the cohorts of chronic, acute, and resolved HBV patients and healthy vaccinated and unvaccinated subjects from this 
study
Clinical phases of HBV infection Number of subjects Age (yr) HBsAg (log IU/ml) HBV DNA (log IU/ml) ALT (IU/l)
Chronic HBeAg+ chronic infection  
(immune tolerant)
22 23 ± 6 4.6 ± 0.45 8.5 ± 0.77 29.7 ± 11.8
HBeAg+ chronic hepatitis  
(immune reactive)
24 25 ± 4.7 3.9 ± 1.3 6.3 ± 2.5 65.6 ± 38.6
HBeAg– chronic hepatitis  
(immune reactive) 
24 27 ± 2.5 3.6 ± 0.6 4.5 ± 1.4 68.8 ± 81.2
HBeAg– chronic infection  
(inactive carrier)
26 24 ± 4.2 3.5 ± 0.76 2.2 ± 0.7 28.9 ± 19.6
Acute 11 (6 subjects longitudinal) 33 ± 9.5 Positive Positive 1865 ± 1141
Resolved (anti-HBs+, anti-HBc IgG+, HBsAg–) 21 ? Negative Negative ND
Healthy vaccinated 18 31.6 ± 4.2 Negative Negative ND
Healthy unvaccinated 5 45.8 ± 20.3 Negative Negative ND
ND, not determined.
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Figure 1. Fluorescently labeled HBsAg baits bind specifically to HBsAg-specific B cells. (A) Schematic representation of fluorescently labeled HBsAg 
baits binding to the BCR on the surface of HBsAg-specific B cells. A healthy subject received an HBV booster vaccination. Serum and blood samples were 
analyzed from day 0 to day 60 after vaccination. (B) Anti-HBs titers in the serum from day 0 to day 60 after vaccination. (C) Frequency of total plasmablasts 
(CD19+CD10–CD21–/loCD27++CD38++) out of total B cells measured longitudinally. (D) Flow cytometry plots show the frequency of HBsAg double-binding MBCs 
(top panel) and their percentages displaying a plasmablast phenotype (bottom panel). The first plot at the left shows data of a healthy unvaccinated 
subject. The other plots show data of a healthy vaccinated subject at the indicated time points before and after the HBV booster vaccination. (E) Frequency 
of HBsAg double-binding MBCs over time. (F) MFI of HBsAg-D550 and HBsAg-D650 on HBsAg-specific B cells at different time points. (G) Equal numbers 
of HBsAg-D550+D650+ and HBsAg-D550–D650– MBCs were FACS sorted from PBMCs of day 60 after booster vaccination and triggered for Ab production by 
CpG and sCD40L polyclonal activation. Cells were cultured in 2 different steps with different cytokine mixtures. Subsequently, anti-HBs ELISA and anti-HBs 
ELISpot assays were performed on culture supernatants and on the cells, respectively.
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We hypothesized that the marked variability of HBsAg-specific 
B cells detected in CHB patients may be related to the genotype 
of the infecting virus. Since our fluorochrome-conjugated HBsAg 
reagents are based on HBV genotype A, a possibility is that our 
reagents would preferentially bind B cells specific for HBsAg geno-
type A or D (which are genetically closely related), but not B cells 
specific for other genotypes (B, C, and E, which are more distant).
Accordingly, the HBV genotypes for 51 out of 96 CHB patients 
were determined. As shown in Figure 2D, a similar frequency of 
HBsAg-specific B cells was detected in CHB patients irrespec-
tive of the genotype of the infecting virus. Thus, the frequency 
of HBsAg-specific B cells is comparable in patients irrespective 
of their natural history stage. This contrasts with the features of 
HBV-specific T cells, which are present in higher frequencies in 
patients who resolve HBV than in those with CHB infection (33).
In order to further analyze the relationship between HBsAg-
specific B cell frequency and viral control, we studied patients 
with acute hepatitis B infection from the time of onset of clinical 
symptoms to functional cure (i.e., HBV DNA negativity, HBsAg 
loss, and detection of anti-HBs).
First, we investigated whether the B cell compartment is 
activated during acute hepatitis B. We thus measured the fre-
quency of plasmablasts (CD19+, CD10–, CD21–, CD27hi, CD38hi) 
in 6 acute hepatitis B patients and, as controls, in 5 patients with 
acute dengue infection (Figure 3A). Frequency of plasmablasts 
was extremely low in 5 out of the 6 patients analyzed at all the dif-
ferent time points. A single subject showed a frequency of 6.5% 
of plasmablasts out of total B cells at the onset of acute hepatitis. 
In contrast, high frequency of plasmablasts was easily detected 
(16%–37% of total B cells) in 4 of the 5 acute dengue patients stud-
ied within a week of the onset of dengue symptoms. Their detec-
tion was transient, since 2 weeks after the acute phase, the plas-
HBs+ and anti–HBV core+ [anti-HBc+]) as well as 96 CHB patients 
(HBsAg+) divided into the following clinical phases: 22 HBV 
e-antigen+ (HBeAg+) chronic infection, 24 HBeAg+ chronic hepati-
tis, 24 HBeAg– chronic hepatitis, and 26 HBeAg– chronic infection 
(32). In addition, PBMCs of 5 healthy non–HBV-vaccinated sub-
jects (anti-HBs and anti-HBc negative) were included as controls.
Figure 2A shows the frequency of HBsAg-specific B cells in 
the different cohorts. HBsAg-D550+/650+ B cells were detected 
at variable frequencies in all HBV-vaccinated subjects and HBV-
infected patients tested. In contrast, they were not detected in 4 
out of the 5 healthy nonvaccinated controls and were detected 
only at a very low frequency (0.01% of total B cells) in 1 of these 
controls, demonstrating the high specificity of the dual-staining 
detection method.
The median (interquartile range) frequency of HBsAg-specific 
B cells in the different cohorts was remarkably similar (vaccinated, 
0.065% [0.035%–0.088%]; acute, 0.053% [0.026%–0.094%]; 
resolved, 0.041%[0.025%–0.074%); chronic, 0.079%[0.048%–
0.12%]), even though it was slightly higher in patients with CHB 
versus those with resolved infection. There was large variability of 
HBsAg-specific B cell frequencies between different subjects with 
CHB, in whom HBsAg-specific B cells could be detected at levels 
ranging from to 0.01% to 0.43% of total B cells. However, these 
different frequencies were not associated with distinct clinical or 
virological profiles of HBV infection. Deconvolution of HBsAg-
specific B cell frequency in different categories of CHB patients 
showed comparable variability in all phases of CHB (Figure 2B), 
with the median frequency (approximately 0.1% of total B cells) 
identical in all cohorts of CHB patients. There was also no statis-
tically significant association between HBsAg-specific B cell fre-
quency and serum levels of HBsAg, HBV DNA, and alanine ami-
notransferase (ALT) (Figure 2C).
Figure 2. Similar frequency of HBsAg-specific B cells in diverse cohorts of HBV-infected patients. (A) Frequency of HBsAg-specific B cells in 5 healthy 
HBV-unvaccinated (HC unvac), 18 healthy HBV-vaccinated (HC vac), 11 acute HBV, 21 resolved HBV, and 96 CHB patients out of total CD19+ B cells. (B) 
Frequency of HBsAg-specific B cells out of total CD19+ B cells in different phases of CHB: 22 HBeAg+ chronic infection (eAg+CInf), 24 HBeAg+ chronic 
hepatitis (eAg+CHep), 24 HBeAg– chronic hepatitis (eAg–CHep), and 26 HBeAg– chronic infection (eAg–CInf). (C) No correlation between frequency of HBsAg-
specific B cells and serum levels of HBsAg, HBV DNA, and ALT. (D) Frequency of HBsAg-specific B cells among 51 CHB patients infected with 5 different 
HBV genotypes. Data are presented as median, and statistical analysis was performed by the Kruskal-Wallis test followed by Dunn’s multiple comparisons 
test. *P < 0.05 (A, B, and D); Spearman’s rank correlation (C).
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anti-HBs Abs were detected at very low titers only in 1 of the 14 
HBsAg-specific B cell cultures tested (Figure 4B).
We reasoned that HBsAg-specific B cells present in CHB 
patients might require help from feeder cells to properly expand. 
We thus adopted a different protocol of B cell maturation that uti-
lizes fibroblasts overexpressing CD40L as feeder cells and specific 
cytokines (IL-2 and IL-21) (34). Similar numbers of HBsAg-specific 
B cells were again sorted from 16 CHB patients and from 8 healthy 
controls, expanded for 13 days, and then analyzed for the presence 
of anti-HBs–secreting cells by ELISpot assay. Figure 4C shows that 
we were able to recover the ability of HBsAg-specific B cells to 
mature into anti-HBs–secreting B cells in 11 out of 16 tested CHB 
patients. With this method, the sorted cells survived and expanded 
well, but their maturation capacity was still compromised (mean 
spot counts: healthy = 240 spots, CHB = 22 spots). Taken together, 
these data directly demonstrate that functional impairment affects 
HBsAg-specific B cells of CHB patients in comparison with those 
present in healthy vaccinated individuals.
In addition, we analyzed the functionality of HBsAg-specific 
B cells present in acute hepatitis B patients. HBsAg-specific B cells 
were sorted at the indicated time points from PBMCs of 5 acute 
patients (Figure 5) and were expanded using the 2 protocols (with 
or without feeder cells) utilized to expand HBsAg-specific B cells 
of CHB patients. Note that the limited sample availability made it 
impossible to test the HBsAg-specific B cells from the same patient 
and time point with both protocols. Anti-HBs titers in the super-
natants (Figure 5A) and quantity of anti–HBs-producing B cells 
(Figure 5B) were measured after 7 or 13 days of expansion. Surpris-
ingly, HBsAg-specific B cells of acute HBV patients sorted during 
the acute phase of hepatitis B (HBsAg+ phase), similarly to those 
of CHB patients, did not differentiate from Ab-secreting cells 
and did not produce Abs irrespective of their expansion method. 
In contrast, HBsAg-specific B cells sorted from PBMCs collect-
ed after HBsAg seroconversion in 3 out of the 3 tested patients 
mablast frequency fell below 1.5% of total B cells. Thus, during the 
symptomatic phase of acute hepatitis B, the initiation of a B cell 
response is not detectable in the circulating compartment. In line 
with the lack of a robust B cell response, the frequency of HBsAg-
specific B cells remained remarkably stable in all of the 6 acute 
HBV patients analyzed over time despite the changes in HBV DNA 
and ALT and the development of anti-HBs Ab (Figure 3B). HBsAg-
specific B cell frequency during acute hepatitis B was similar to the 
frequency detected in resolved patients (anti-HBs+ and anti-HBc+ 
patients with a history of hepatitis). Thus, the B cell immunity 
profile appears remarkably stable during the acute symptomatic 
phase of acute hepatitis B, and the quantity of circulating HBsAg-
specific B cells does not correlate with that of HBV control.
Function of HBsAg-specific B cells during HBV infection. The 
lack of correlation between HBsAg-specific B cell frequency and 
HBV control might indicate that HBsAg-specific B cells present in 
different groups of HBV-infected subjects have functional differ-
ences. Indications that anti-HBs–producing B cells are function-
ally altered in CHB infection have already been suggested by data 
derived from the analysis of bulk B cells (15–17).
To further decipher the functionality of HBsAg-specific B 
cells, we sorted HBsAg-specific B cells from 14 CHB patients and 
measured their ability to proliferate and mature into Ab-secret-
ing B cells. HBsAg-specific B cells of healthy vaccinated individ-
uals (4 subjects) were also sorted as controls. HBsAg-specific B 
cells of all 4 vaccinated individuals expanded in vitro and pro-
duced anti-HBs Abs (Figure 4A). However, microscopic inspec-
tion of the cell culture of HBsAg-specific B cells of CHB patients 
revealed that, in most of the cases, B cells expanded poorly or 
disappeared. ELISpot assays to analyze the frequency of HBV-
specific B cells were performed in only 5 chronic patients, and 
anti-HBs Ab spots were detected in a single culture (Figure 4A). 
Parallel analysis of anti-HBs Ab titers in supernatants of all cul-
tured HBAg-specific B cells of CHB patients confirmed that 
Figure 3. Longitudinal profile of B cell responses in acute HBV patients. (A) Frequency of global plasmablasts (CD19+CD10–CD21–CD27++CD38++) out of total 
B cells (CD19+) were analyzed at the indicated different time points in 6 patients with acute HBV (left) and in 5 patients with acute dengue infection (right). 
Time points are indicated as days after onset of clinical symptoms. Virological features of acute HBV and dengue are indicated at the top of the figures. 
(B) Longitudinal frequency of HBsAg-specific B cells in the 6 acute hepatitis B patients compared with the frequency obtained in 21 subjects with resolved 
HBV infection (anti-HBc+, anti-HBs+; open circles). HBsAg-specific B cells were calculated as the frequency of memory double-positive HBsAg-D550+D650+ 
B cells out of total CD19+ B cells. Each symbol represents a single patient.
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expanded and produced anti-HBs (Figure 5, A and B). Thus, 
HBsAg-specific B cells present during acute HBV infection display 
functional impairment similar to those detected in CHB patients, 
but recover their functionality after HBsAg+ seroconversion. Con-
jointly, the data obtained in chronic and acute HBV patients sug-
gest that HBsAg modulates the functionality of HBsAg-specific B 
cells irrespective of the outcome of HBV infection.
Phenotype of B cells during HBV infection. To understand the 
possible causes of the impaired functionality of HBsAg-specific B 
cells, we analyzed and compared the phenotype of HBsAg-specific 
and total B cells present in patients with acute and chronic HBV 
as well as in those with resolved infection along with vaccinated 
subjects. In other chronic infections (e.g., HCV, HIV, and malaria), 
B cells, with reduced expression of the complement receptor type 
2 (CD21) and of the memory marker CD27, are present in aug-
mented frequencies. They are defined as atypical memory (AtM) 
B cells and show a reduced ability to proliferate and produce Abs 
after stimulation with B cell activators (3–5).
To characterize the phenotype of HBsAg-specific B cells, we 
performed analysis of flow cytometric data using the algorithm 
Uniform Manifold Approximation and Projection (UMAP). This 
algorithm enables visualization of high-dimensional cell param-
eters in a 2D map by plotting cells with similar phenotypes in close 
proximity (35). Live total MBCs (CD19+CD10–; CD21+CD27– naive 
B cells excluded) and HBsAg-D550+/650+ MBCs from a total of 
141 samples were concatenated and analyzed for the expression 
of markers that define MBC subsets (CD21, CD24, CD27, CD38, 
IgG) and their activation status (CD19, CD23, CD39, CD69, CD73, 
CD95, HLA-DR, PD-1). UMAP analysis automatically separated 
plasmablasts (CD24–CD38hi), classical IgG+ and IgG– MBCs, and 
AtM B cells (CD21–CD27–) (Figure 6A).
Next, we analyzed the phenotypic profile of HBsAg-specific 
B cells from 15 healthy vaccinated and 76 CHB patients with dif-
ferent disease phases by overlaying them onto the concatenated 
UMAP of total MBCs (Figure 6B). This revealed that HBsAg- 
specific B cells generally have a heterogeneous phenotype; how-
ever, in CHB patients only, we detected an accumulation of 
HBsAg-specific cells within the cluster of AtM B cells. While only 
5.5% of HBsAg-D550+/650+ B cells from healthy vaccinated sub-
jects were present within the AtM cluster defined by UMAP, the 
number was 14.7% for CHB patients (Figure 6C).
Since UMAP did not separate the classical CD21+CD27+ rest-
ing memory (RM) and CD21–CD27+ activated memory (AM) MBC 
subsets and only allows comparison of samples stained with an 
identical Ab panel, we also quantified the phenotypic distribution 
of HBsAg-specific and total B cells using manual gating strategies 
(Supplemental Figure 2). This showed clearly that most HBsAg-
specific B cells of healthy vaccinated and CHB patients displayed 
a phenotype of RM B cells and confirmed again that a significantly 
higher proportion of HBsAg-specific B cells of CHB patients dis-
Figure 4. HBsAg-specific B cells from CHB patients are dysfunctional and require coculture with CD40L-expressing 
feeder cells for survival, expansion, and anti-HBs production. (A) HBsAg-specific B cells from 4 healthy vaccinated 
donors and 14 CHB patients were FACS sorted and cultured in the presence of CpG, sCD40L, IL-2, IL-10, and IL-15 for 
4 days and subsequently with IL-2, IL-6, IL-10, and IL-15 for another 3 days before the anti-HBs ELISpot assays were 
performed. nd, not done due to low cell number. The chart shows the percentage of anti-HBs producers. Dark gray 
indicates positive. (B) Supernatants of the cultured specific B cells (from A) were taken after 7 days culture, and 
anti-HBs levels were measured by ELISA. Data are presented as median, and statistical analysis was performed 
by Mann-Whitney U test. ***P < 0.001. (C) HBsAg-specific B cells from 8 healthy vaccinated donors and 16 CHB 
patients were FACS sorted and cocultured with CD40L-expressing feeder cells in the presence of IL-2 and IL-21 for 13 
days before anti-HBs ELISpot assays were performed. Chart shows the percentage of anti-HBs producers. Dark gray 
indicates positive.
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played an AtM phenotype (16.6% CHB, 8.4% HBV vaccinated; 
P = 0.01; Supplemental Figure 2).
The frequency of HBsAg-specific B cells with an AtM pheno-
type was identical in different cohorts of CHB patients (Figure 6C) 
and was not correlated with HBsAg quantity, HBV DNA, or ALT 
(Supplemental Figure 3). Importantly, the modification of the B 
cell phenotype was not selectively present in the HBsAg-specific 
B cell compartment, but an enriched frequency of AtM was also 
detected in total B cells, which declined with progressing phases 
of CHB infection (Figure 6D). In line with this decline, we found 
a positive correlation between HBV DNA values and frequency of 
global AtM B cells, but not with serum HBsAg levels (Figure 6E).
In addition, we analyzed to determine whether HBsAg-spe-
cific B cells present during the HBsAg+ serological phase of acute 
hepatitis were associated with a preferential AtM phenotype 
(Figure 6, F and G). Despite the significant decline of HBV DNA, 
ALT, and HBsAg values during the course of acute hepatitis B, 
we failed to detect any consistent pattern in terms of AtM pheno-
type frequency of HBsAg-specific B cells at different time points 
during acute hepatitis (Figure 6G). One patient had a very high 
frequency (67%) of HBsAg-specific B cells with an AtM pheno-
type at the onset of acute HBV infection, and in this patient, the 
HBsAg-specific B cells with an AtM phenotype decreased sharply 
over time (Figure 6G). Yet the overall frequency of AtM in HBsAg-
specific B cells of patients with acute HBV infection was not sta-
tistically different from that in resolved or vaccinated subjects 
(Figure 6F). However, the global B cell compartment of acute 
HBV patients was significantly enriched for AtM in comparison 
with that of healthy vaccinated subjects (Figure 6H). Again, we 
found no consistent pattern of global AtM frequency during acute 
hepatitis B (Figure 6I).
Alteration of the global B cell compartment during HBV infection. 
The increased frequency of total B cells with an AtM phenotype 
supports the notion that HBV infection might influence, not only 
the HBV-specific, but also the global B cell compartment. Evi-
dence of the impact of HBV infection on total B cells has been pre-
viously reported (13, 36). We analyzed the transcriptional profile 
of the 4 different mature B cell subsets of healthy vaccinated and 
CHB patients with high viral replication and absence of inflamma-
tion (HBeAg+ chronic infection). CD19+CD10– B cells were sorted 
based on their expression of CD21 and CD27 (Figure 7A). In par-
allel, naive and memory populations of CD4+ and CD8+ T cells, 
using anti-CCR7 and anti-CD45RA, were also sorted to determine 
whether differential gene expression is more pronounced on the B 
or T cell compartment (Figure 7B). First, to better understand the 
properties of AtM B cells present in CHB patients, we compared 
their gene expression profile to those of classical MBCs, RM, and 
AM (Supplemental Figure 4). This revealed that they are similar to 
AtM B cells found enriched in patients with persistent HIV, HCV, 
and Plasmodium falciparum infection, characterized by upregula-
tion of, e.g., TBX21, FCRL5, FCRL3, LILRB2, and SIGLEC6 and 
downregulation of CCR7, SELL, and IL13RA (3, 4, 37–39). More-
over, after sorting the different global MBC subsets, we confirmed 
that AtM B cells enriched in CHB patients were similarly defective 
Figure 5. Functional characterization of HBsAg-specific B cells during acute hepatitis B. (A) HBsAg-specific B cells were sorted from PBMCs of 3 patients 
at different time points after onset of acute hepatitis B (AHB). The schematic graph on the top indicates the different serological and clinical parameters 
(ALT, HBsAg, and HBV DNA) at which PBMCs were collected. Sorted HBsAg-specific B cells were polyclonal stimulated with CpG, sCD40L, IL-2, IL-10, and 
IL-15 for 4 days and subsequently cultured with IL-2, IL-6, IL-10, and IL-15 for another 3 days. After 7 days, culture supernatants were collected and tested in 
an anti-HBs–specific ELISA. Bars indicate the optical density of detected anti-HBs Ab. (B) HBsAg-specific B cells were sorted from PBMCs of 2 additional 
acute hepatitis B patients at the indicated time points. Sorted HBsAg-specific B cells were expanded on CD40L-expressing fibroblasts with the addition of 
IL-2 and IL-21 for 13 days. Expanded cells were tested on anti-HBs B cell ELISpot. Bars indicate the numbers of spots obtained.
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Figure 6. HBsAg-specific and global B cells of CHB patients are enriched for an AtM phenotype. (A) Flow cytometric data of MBCs from 15 healthy 
vaccinated, 11 early acute, 20 late acute, 19 resolved, and 76 CHB patients were analyzed by the dimensionality reduction algorithm UMAP and 
concatenated. Four different MBC subsets were delineated (left panel) based on the expression heatmaps of 13 markers (right panels). (B) HBsAg-specific 
B cells from 15 healthy vaccinated, 20 HBeAg+ chronic infection, 15 HBeAg+ chronic hepatitis, 18 HBeAg– chronic hepatitis, and 23 HBeAg– chronic infection 
patients were concatenated, normalized to their correct frequency, and overlaid onto the UMAP plot of global concatenated MBCs. (C) Frequency of AtM B 
cells among HBsAg-specific B cells within the different cohorts. (D) Frequency of global AtM B cells among total B cells (CD19+) present in the subjects of 
the different cohorts. (E) Correlation of frequency of global AtM among total B cells with serum HBsAg (left), HBV DNA (middle), and ALT (right) levels. (F) 
Overlay of HBsAg-specific B cells on global MBCs of 11 concatenated acute (left) and 19 resolved (right) HBV patients. (G) Percentage of HBsAg-specific B 
cells with an AtM phenotype in 6 acute HBV patients at different time points from disease onset. Each symbol represents a single patient. (H) Percentage 
of global AtM B cells among total B cells (CD19+) of healthy vaccinated, acute, and resolved HBV patients. (I) Percentage of global AtM B cells in 6 acute 
HBV patients at different time points from disease onset. Bar graphs present median, and statistical analysis was performed by the Kruskal-Wallis test 
followed by Dunn’s multiple comparisons test (C, D, and H) and Spearman’s rank correlation (E). *P < 0.05; **P < 0.01.
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Figure 7. Transcriptional alteration of global B cell subsets by CHB infection. (A) Four different mature (CD19+CD10–) B cell populations from 5 CHB 
patients (CHB; eAg+CInf) and 4 healthy vaccinated subjects were FACS sorted based on their expression of CD21 and CD27 (see gating strategy). Cells were 
lysed, and mRNA expression levels of 588 immune-related genes were measured by NanoString. Heatmaps showing immune genes that are significantly 
different between CHB and healthy vaccinated subjects (P < 0.05, ≥2-fold different) within the 4 different B cell subsets, naive, RM, AM, and AtM. (B) Four 
different subsets of global CD4+ and CD8+ T cells (CD3+) were sorted from 6 CHB patients and 5 healthy vaccinated controls based on their expression of 
CCR7 and CD45RA (see gating strategy) and analyzed by NanoString. EM, effector memory; CM, central memory. Heatmaps showing immune genes that 
are significantly different between CHB and healthy vaccinated subjects (P < 0.05, ≥2-fold different) within the different T cell subsets.
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Among the most upregulated genes in B cells of CHB patients 
were some related to B cell activation, such as CD83, a costimula-
tory molecule induced on B cells by activated T cells through CD40 
engagement (40). CD83 was upregulated on naive, RM, and AtM B 
cells of CHB patients. Also, all 4 B cell populations present in CHB 
patients upregulated NFKBIZ, which is induced following BCR 
or TLR stimulation (41). We also noted differential expression of 
genes involved in B cell differentiation. DUSP4, a tumor-suppres-
sor gene in B cell lymphoma, was upregulated by 9.8-fold in AtM 
of CHB patients compared with healthy controls. It has a role in 
inhibiting cell proliferation and differentiation through the inhibi-
tion of MAPK. We also observed that ICAM-2 was downregulated 
in expansion and differentiation into Ab-secreting cells (total IgG) 
upon polyclonal CpG activation (Supplemental Figure 4B).
Then we analyzed to determine whether the 4 B cell subsets 
(naive, RM, AM, and AtM) of healthy and CHB patients display dif-
ferences in their gene expression profile. In all the 4 B cell subsets 
combined, a total of 55 genes were differentially regulated (>2-fold 
different, P < 0.05; total of 588 immune genes measured), but the 
AtM B cells were the more diversified by HBV infection, with 32 
genes differentially regulated. Strikingly, the gene expression pro-
files of naive and memory CD4+ and CD8+ T cells of CHB patients 
and healthy controls were more homogeneous, with only 12 genes 
differentially regulated in the 7 T cell populations compared.
Figure 8. PD-1 blockage partially recovers dysfunctional HBsAg-specific B cells of CHB patients. (A) mRNA expression of PD-1 in the indicated B cell 
subsets of 5 CHB patients measured by NanoString. (B) Surface PD-1 expression on the B cell subsets of 96 CHB patients measured by flow cytometry. 
(C) Flow cytometric data of MBCs from 141 samples analyzed by UMAP and concatenated. Four subsets of MBCs were delineated (left, plots reshown 
from Figure 6A), and PD-1+ MBCs are shown (right). (D) MBCs of 15 healthy vaccinated (left) and 76 CHB patients (right) were downsampled to equal cell 
numbers. Density UMAP plots are shown; the cluster of AtM B cells is highlighted in red. Right bar graph shows percentage of global MBCs with an AtM 
phenotype in 17 healthy vaccinated and 96 CHB patients. (E) Double-positive HBsAg-D550+D650+ B cells from 15 healthy vaccinated (left) and 76 CHB 
patients (right) were concatenated, downsampled to normalized frequencies, and overlaid onto the UMAP plot of global concatenated MBCs; the cluster 
of AtM B cells is highlighted in red. Right bar graph shows percentage of HBsAg-specific B cells with an AtM phenotype in healthy vaccinated and CHB 
patients. (F) MFI of PD-1 on global MBCs and HBsAg-specific MBCs of 96 CHB patients. (G) Double-positive HBsAg-D550+D650+ MBCs from 4 CHB patients 
and 3 healthy vaccinated subjects were FACS sorted and cocultured for 13 days with CD40L-expressing feeder cells in the presence of IL-2 and IL-21, with 
or without anti–PD-1 Ab (schematic at left). Subsequently, anti-HBs–secreting cells were detected by ELISpot assay (right). Average fold changes in the 
number of anti-HBs spots are shown above the plots. Data are presented as median, and statistical analysis was performed by the Mann-Whitney U test 
(D and E) and Wilcoxon’s paired t test (F and G). *P < 0.05; **P < 0.01; ****P < 0.0001.
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the numbers of circulating HBsAg-specific B cells are stable dur-
ing the symptomatic phase of acute HBV infection despite the 
robust changes in HBV DNA and HBsAg levels characteristic of 
acute hepatitis B.
These findings differ from circulating HBV-specific T cell fre-
quency, which is inversely proportional to the level of HBV DNA 
in adult patients with CHB infection (33) and fluctuates vigorously 
during acute hepatitis B (46). At first sight, this discrepancy could 
be interpreted as a sign that B cells have a limited role in control-
ling HBV, but the ability of HBV-specific MBCs to suppress HBV is 
indirectly supported by data from rituximab-treated subjects (47, 
48). CD20-expressing B cell depletion treatment is known to trig-
ger HBV reactivation in a high proportion of anti-HBc+ subjects, 
and the importance of HBsAg-specific B cells during HBV infec-
tion is confirmed by our functional data. Indeed, the second clear 
observation of our work is that, while the frequency of circulating 
HBsAg-specific B cells is independent of the stage of HBV infec-
tion, their function is influenced by the presence of HBV infection 
itself and in particular by the presence or absence of serum HBsAg.
HBsAg-specific B cells of vaccinated individuals and of HBV-
infected patients that have resolved HBV infection (anti-HBs+ and 
anti-HBc+) efficiently mature in vitro with different expansion/
differentiation protocols. In contrast, HBsAg-specific B cells sort-
ed from both chronic and acute (still in the HBsAg+ phase) HBV-
infected patients demonstrate clear functional defects. First, they 
were substantially unable to expand without the presence of feeder 
cells expressing CD40L. Furthermore, even though HBsAg-specif-
ic B cells were not completely exhausted and could be recovered in 
some CHB patients, their ability to expand and/or differentiate in 
the presence of CD40L interaction and cytokines (IL-2 and IL-21) 
remains defective in comparison with HBsAg-specific B cells pres-
ent in HBsAg-negative subjects. These data confirm the historical 
work performed with bulk B cells that has indicated specific func-
tional defects of HBsAg-specific B cells in CHB patients (15–17).
However, our demonstration that HBsAg-specific B cells 
of CHB patients can be partially rescued in vitro suggests that a 
residual functionality of HBsAg-specific B cells could be main-
tained in vivo in the presence of T helper and Tfh cells or in the 
proper anatomical location (lymph node) (49). This could explain 
why anti-HBs Abs can still be measured in the form of immuno-
complexes in CHB patients (19).
At the moment, the causes of the partial functional defects 
of HBsAg-specific B cells are not entirely clear. HBsAg-specific B 
cells are likely to directly interact with the circulating HBsAg via 
their specific BCRs, and this might provide prolonged stimulatory 
signals to specific B cells and result in their terminal differentia-
tion and functional exhaustion, as seen in other persistent infec-
tions (3–5). Such a scenario fits with the maturation defects of 
HBsAg-specific B cells present in patients with HBsAg positivity, 
but it is somehow surprising that we could not find any associations 
between HBsAg quantity and functional defects. For example, the 
ability of CD40L feeder cells to rescue HBsAg-specific B cell func-
tion was detected in CHB patients characterized by different clini-
cal and virological profiles (HBsAg and HBV DNA quantity).
Similarly, the phenotype of HBsAg-specific B cells present in 
CHB patients only partially fits with their functional defects. An 
enrichment of HBsAg-specific B cells with a phenotype of atypi-
on AM and AtM B cells (CD21lo B cells) of CHB patients. ICAM-2 
is essential for long-lasting cognate T follicular helper (Tfh)/B cell 
interactions and efficient selection of low-affinity B cell clones for 
proliferative clonal expansion (42). Importantly, we detected an 
increased expression of PD-1 within AtM B cells of CHB-infected 
patients. A hallmark of CHB infection is the presence of exhaust-
ed HBV-specific T cells (8), but whether HBV infection can affect 
the global B and T cell populations remains controversial. In the 
5 CHB patients studied here, unlike what occurs in AtM B cells, 
the activation inhibitor PD-1 was not overexpressed in any of the 
tested T cell subsets of CHB patients.
Collectively, these data show that HBV infection appears to 
exert a more pronounced impact on the global B cell than T cell pop-
ulation and that functional modulation is not restricted to HBsAg-
specific B cells, but is also seen in the global B cell compartment.
Rescue of HBsAg-specific B cell function with anti–PD-1 Abs. 
Increased mRNA expression of PD-1 in AtM B cells of CHB 
patients led us to hypothesize that PD-1 blockade can further 
boost HBsAg-specific B cell differentiation into Ab-secreting 
cells. PD-1 is a negative regulator of T cell activation, but it is 
also expressed by B cells and can regulate human B cell matura-
tion (43). Importantly, siRNA downregulation of PD-1 expression 
recovers the HIV-specific exhausted B cell response (44), and 
anti–PD-1 treatment of SIV-infected macaques boosts functional-
ity of antiviral T and B cells (45).
We determined that mRNA and protein expression of PD-1 
were elevated on AM and specifically AtM B cells compared with 
the classical RM B cells (Figure 8, A–C). In addition, the global 
AtM B cell population was enriched by HBV infection (Figure 8D) 
and was also enriched in HBsAg-specific B cells of chronically 
infected patients (Figure 8E). Since HBsAg-specific B cells express 
higher levels of PD-1 compared with global MBCs (Figure 8F), we 
tested in vitro whether PD-1 blockade can affect the Ab-secreting 
cell maturation of HBsAg-specific B cells present in CHB patients.
Sorted HBsAg-specific B cells of 4 CHB patients (3 HBeAg+ 
infection, 1 HBeAg+ hepatitis) and 3 healthy vaccinated subjects 
were cultured with CD40L-expressing fibroblasts with or with-
out anti–PD-1 Ab. Figure 8G shows that anti–PD-1 treatment was 
able to increase the number of anti-HBs–producing B cells prefer-
entially in the CHB patients tested. The ability to mature into Ab-
secreting cells increased on average by 9.7-fold in the CHB patients 
and by 1.6-fold in healthy vaccinated subjects. Although the num-
ber of Ab-producing cells was still lower in CHB patients, our data 
demonstrate that PD-1 blockade can partially restore the anti-HBs 
secretory ability of HBsAg-specific B cells.
Discussion
We performed here a comprehensive ex vivo analysis of the fre-
quency, function, and phenotype of HBsAg-specific B cells in 
patients with different profiles of HBV infection. This study allows 
us to begin to define the features of humoral immunity against 
HBV, which has previously been largely neglected.
The first observation is that the quantity of circulating HBsAg-
specific B cells is remarkably similar in vaccinated subjects and in 
patients with acute or chronic HBV infection. We did not find any 
associations between the frequency of HBsAg-specific B cells and 
HBsAg or HBV DNA quantity in chronic infection. Furthermore, 
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of their antigen specificity or whether the analysis with fluoro-
chrome-conjugated HBsAg underestimates the HBV-specific B 
cell quantity. At the moment, our data indicate that both HBsAg-
specific and total B cells are altered and that the total B cell altera-
tion is more pronounced than what we detected on total T cells. 
This observation is in line with data showing that only a few total 
T cells express more exhaustion markers in CHB patients than in 
healthy individuals (55) and also with reports of preferential mod-
ifications of gene signatures of B cells induced by CHB infection 
(13, 36). The unanswered question is whether the modifications of 
both HBsAg-specific and total B cells are caused only by circulat-
ing HBsAg, other viral products, or by mechanisms not linked to 
virological products, such as an altered intrahepatic environment 
present in CHB patients, as suggested by Burton et al. (50). The 
full understanding of the contribution of these mechanisms on B 
cell functionality in CHB infection will be important for select-
ing the new therapeutic strategies that aim to recover the faulted 
HBV-specific immunity present in CHB patients and that are now 
entering clinical trials (23, 29, 56).
Agents designed to reduce secretion or synthesis of HBsAg 
might indeed restore HBV immune function, since, to our knowl-
edge, our observation that full HBsAg-specific B cell functionality 
is recovered only at the time of complete negativity of serological 
HBsAg represents what we believe is the first clear observation 
that circulating HBsAg acts, in HBV-infected patients, not only as 
a decoy of anti-HBs Abs (28), but also as a modulator of HBsAg-
specific B cell function. On the other hand, the lack of associations 
between HBsAg quantity and HBsAg-specific B cell defects might 
indicate that partial suppression of HBsAg quantity cannot be suf-
ficient to recover B cell immunity.
In contrast, the findings that anti–PD-1 Abs augment HBsAg-
specific B cell recovery in all CHB patients tested suggest that anti-
PD1 therapy in CHB patients might be able to improve both HBV-
specific T and B cell functionality. This hypothesis is supported 
not only by our in vitro data, but also by the report of the ability of 
anti–PD-1 treatment to recover B cell functionality in SIV–infect-
ed macaques (45). In line with the B cell profile of HIV-infected 
individuals, humoral immunity in SIV-persistent infection should 
share the functional, phenotypic, and transcriptomic alteration 
detected by us (and by the accompanying Burton et al. paper, ref. 
50) in the HBsAg-specific and global B cell compartment of CHB 
patients. Thus, we believe that anti–PD-1 therapy might be able to 
indeed also act on the altered B cell compartment of CHB patients.
In conclusion, dual staining with fluorochrome-conjugated 
HBsAg allowed us to directly visualize HBsAg-specific B cells in 
different categories of HBV-infected and vaccinated subjects and 
decipher the impact that HBV has on humoral adaptive immunity. 
We observed that, while HBV infection status does not affect the 
frequency of circulating HBsAg-specific B cells, the functional 
state of global and HBsAg-specific B cells is robustly affected 
by HBsAg presence. The demonstration that the compromised 
HBsAg-specific B cells of CHB patients are amenable to function-
ally recovering after HBsAg clearance or through utilization of 
anti–PD-1 Abs opens new therapeutic possibilities for achieving 
HBV functional cure and calls for a precise monitoring of B cell 
function during future clinical trials with new agents designed to 
boost HBV-specific immunity.
cal MBCs is clearly present in CHB patients (our data and Burton 
et al., ref. 50). These B cells were characterized by low CD21 and 
high CD69 and PD-1 expression, compatible with overstimulation 
and exhaustion. However, in all of the CHB patients studied here, 
such phenotypic features affect on average only approximately 
15% of the HBsAg-specific B cells. Furthermore, HBsAg-specific B 
cells detected during acute hepatitis B are unable to expand and/
or differentiate in vitro, but they did not display the phenotypic 
features detected in cells of CHB patients.
Analysis of gene expression at the single-cell level will be 
necessary to understand whether multiple mechanisms able to 
suppress the in vitro maturation of the different populations of 
HBsAg-specific B cells exist in vivo. At the moment, the technical 
challenge of sorting a sizeable number of HBsAg-specific B cells of 
different phenotypes (AtM, RM, and AM) precludes this analysis.
In addition, an in-depth analysis of HBV-specific T helper 
cells and especially Tfh cells, which provide help for B cell matura-
tion via CD40L and IL-21 in the germinal center, in association 
with B cells will be important for better understanding the causes 
of HBsAg-specific B cell defects. Recent data in mouse models 
have shown the importance of boosting the T helper and Tfh cell 
responses for HBsAg seroconversion (51, 52), but data on Tfh cells 
in humans remain limited (53).
One other limitation of our analysis needs to be highlighted: 
the circulating compartment could not be the correct anatomi-
cal location for B cell quantity and functional analysis. The vast 
majority of B cells resides in the lymph nodes, where the process 
of IgG somatic maturation takes place (49). In addition, HBsAg-
specific B cells can also be compartmentalized, not only in spleen 
and lymph nodes, but also in HBV chronic infected livers, as 
recently detected by Burton et al. (50). However, the finding 
that both circulating and intrahepatic B cells of CHB patients are 
enriched of atypical MBCs (50) demonstrates that the circulat-
ing compartment is representative of the global B cell features of 
HBV-infected patients.
We should also consider the fact that our method based on the 
use of recombinant HBsAg likely underestimated the real num-
ber of total HBsAg-specific B cells in HBV-infected patients. Abs 
recognize not only linear, but also conformational epitopes. The 
recombinant HBsAg used in our approach, although produced in 
mammalian cells (54), may have a different conformation than 
the natural envelope protein synthesized by infectious hepato-
cytes and present on the surface of the virions and of the defective 
HBsAg particles. In addition, circulating HBsAg could mask some 
HBsAg-specific B cells. Both issues make it likely that in HBV-
infected patients, the absolute quantity of HBsAg-specific B cells 
is higher than what we can measure.
Perhaps this inability to visualize the totality of HBsAg- 
specific B cells might partially explain the other interesting find-
ing of our work, the fact that global, non–HBV-specific B cell pop-
ulations display a gene expression profile that was altered by HBV 
infection and share activation of genes involved in hyperstimu-
lation and suppression of differentiation (CD83, DUSP-4) that 
support the B cell maturation defects of HBsAg-specific B cells. It 
will certainly be important to precisely measure the overall size of 
the HBV-specific B cell repertoire. This will allow understanding 
whether HBV infection alters the B cell compartment irrespective 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 5 8 5jci.org   Volume 128   Number 10   October 2018
The optimum concentration of the labeled HBsAg for staining 
was defined by testing samples obtained from healthy vaccinated and 
unvaccinated donors. Different concentrations of the reagents were 
tested for binding to MBCs to select a concentration that had reason-
able staining intensity on B cells with no binding to T cells and minimal 
background staining in unvaccinated subjects (Supplemental Figure 1). 
For the entire study, 1 μg of each reagent/50 μl staining mixture was 
chosen. Analysis of flow cytometry data was performed using FlowJo 
software, version 10 (BD), and the nonlinear dimensionality reduction 
technique UMAP (35). We downsampled the global MBCs to 10,000 
cells per sample and used a logicle transformation with width of lin-
earization (w) = 0.1, top of the scale data value (t) = 500000, total plot 
width in asymptotic decades (m) = 4.5, and additional negative range to 
be included in the display in asymptotic decades (a) = 0.
Cell sorting. Cell sorting was performed for 3 purposes: (a) transcrip-
tional analysis of different subsets of total B cells and CD4+ and CD8+ T 
cells; (b) functional analysis of AtM compared with naive and classical 
MBCs; and (c) functional analysis of HBsAg-specific B cells.
For NanoString analysis on subsets of total B and T cells, PBMCs 
were thawed and directly stained (no enrichment) using the follow-
ing mixture of Abs: (a) T cell staining: anti-CD3, anti-CD19, anti-CD4, 
anti-CD8, anti-CD197 (CCR7), and anti-CD45RA; and (b) B cell stain-
ing: anti-CD3, anti-CD10, anti-CD19, anti-CD21 and anti-CD27. For 
sorting of HBsAg-specific B cells, B cells were preenriched using Easy-
Sep human B Cell Isolation Kit (STEMCELL Technologies) to a purity 
of greater than 95%. Following live/dead staining, cells were stained 
with anti-CD3, anti-CD10, anti-CD19, anti-CD21, and anti-CD27 plus 
HBsAg-D550/650. An average of 300 HBsAg-specific B cells for the 
experiments without feeder cells and 150 specific cells for coculture 
with feeder cells were sorted. All sorts were performed with the FACS-
Aria III machine (BD).
Functional analysis of HBsAg-specific B cells in vitro. All cultures were 
performed in Iscove’s Modified Dulbecco’s Medium (IMDM) (Invitro-
gen) and 10% ultra-low IgG fetal bovine serum (Gibco, Thermo Fisher 
Scientific) supplemented with 50 μg/ml human transferrin and 5 μg/
ml human insulin (Sigma-Aldrich) (now called IMDM complete medi-
um) in U-bottom 96-well culture plates. For functional characteriza-
tion of HBsAg-specific B cells, cells were cultured in 2 different settings 
as follow: (a) sorted HBsAg-specific B cells from preenriched B cells 
of healthy vaccinated, acute, and chronic HBV–infected patients were 
cultured in vitro with optimized conditions for B cell expansion and dif-
ferentiation to Ab-secreting cells reported by M. Jourdan (57) with few 
modifications. Briefly, sorted HBsAg-specific B cells from each subject 
were seeded in 100 μl/well IMDM complete medium containing 20 
U/ml IL-2, 50 ng/ml IL-10, 10 ng/ml IL-15, 10 μg/ml phosphorothio-
ate CpG oligodeoxynucleotide 2006 (ODN) (Invivogen), and 50 ng/
ml monomeric soluble recombinant human CD40L (all cytokines and 
s-CD40L were purchased from R&D Systems). Cells were cultured 4 
days under these conditions (step 1 to stimulate/expand B cells), then 
pelleted and resuspended in new medium containing 20 U/ml IL-2, 50 
ng/ml IL-10, 10 ng/ml IL-15, and 50 ng/ml IL-6. Cells were cultured 
for another 3 days under these condition (step 2) to enhance their dif-
ferentiation to Ab-producing plasmablasts. After 7 days of culture in 
these 2 steps, supernatants were collected and cells were washed and 
resuspended in fresh medium as in step 2 and seeded into ELISpot 
plates. (b) Sorted HBsAg-specific B cells were cocultured with irradi-
ated 3T3-msCD40L feeder cells (3T3-mouse fibroblast cell line over-
Methods
Patients. The healthy (non–HBV infected) group comprised 18 sub-
jects who completed a standard HBsAg vaccination (Engenirix B, 20 
μg HBsAg protein, GSK) scheduled at least 5 years before entering 
the study, with the exception of a subject who performed a new boost 
HBV vaccination and 5 healthy non–HBV-vaccinated subjects (anti-
HBs negative and anti-HBc negative). Furthermore, 21 subjects with a 
clinical history of resolved acute hepatitis (anti-HBc+ and anti-HBs+), 11 
patients with acute hepatitis B (HBsAg+, IgM anti-HBc+, high ALT; lon-
gitudinal samples were obtained from 6 of them), and 96 treatment-
naive patients with CHB infection (HBsAg+) were included. Table 1 
summarizes clinical and virological parameters. CHB patients were 
categorized into standard phases using the criteria outlined in the EASL 
2017 clinical practice guidelines on the management of HBV infection 
(32). Thus, classification and denomination of CHB patients used in 
this work are as follows: (a) HBeAg+ chronic infection (eAg+CInf): nor-
mal ALT (< 40 IU/l), HBeAg+ and high HBV DNA; (b) HBeAg+ chronic 
hepatitis (eAg+CHep): elevated ALT, HBeAg+; (c) HBeAg– chronic hep-
atitis (eAg–CHep): elevated ALT, anti-HBe+; and (d) HBeAg– chronic 
infection (eAg–CInf): normal ALT, anti-HBe+, low HBV DNA (32).
Clinical and virological parameters. On recruitment to the study, 
anti-HBs titers (in vaccinated subjects) or viral serology and HBV DNA 
levels (in HBV-infected subjects) were tested. HBsAg, HBeAg, and 
anti-HBe levels were measured with a chemiluminescent micropar-
ticle immunoassay (chemiluminescent microparticle immunoassay 
[CMIA]; Abbott Architect, Abbott Diagnostics), and where available, 
HBV genotype was recorded. HBV DNA levels in serum were quanti-
fied by real-time PCR (COBAS AmpliPrep/COBAS TaqMan HBV test 
v2.0; Roche Molecular Diagnostics).
Production of fluorescently labeled HBsAg. Recombinant HBsAg 
(genotype A) was produced by Gilead Sciences as described (54). 
For labeling, purified recombinant HBsAg proteins were individu-
ally conjugated with DyLight 550 or DyLight 650 fluorochromes 
(Thermo Scientific) according to the manufacturer’s protocol. 
Briefly, 5 mg HBsAg (1 mg/ml) was mixed with 50 μg of each dye 
and incubated at room temperature (RT) for 1 hour. The labeling was 
neutralized by adding 50 μl of 1 M Tris pH 7. Excess fluorochrome 
was removed by dialysis against PBS. Labeling efficiency was deter-
mined as described in the manufacturer’s protocol (on average 7 dye 
molecules per HBsAg particle).
PBMC isolation and flow cytometry analysis of total and HBsAg-
specific B cells. PBMCs were isolated from peripheral blood by density 
centrifugation using Ficoll-Hypaque Plus (GE Healthcare) and were 
then cryopreserved. Cells were thawed and then directly used for ex 
vivo flow cytometry. For staining experiments, first viability assay was 
performed by incubation of the cells for 10 minutes at RT with Live/
Dead Fixable Blue Stain Reagent (L23105; Life Technologies). A panel 
of 15 mouse anti-human monoclonal Abs against CD3, CD10, CD19, 
CD21, CD23, CD24, CD27, CD38, CD39, CD69, CD73, CD95, HLA-
DR, IgG, and PD-1 (details of Abs in Supplemental Table 1) in combi-
nation with HBsAg-D550 and HBsAg-D650 was used. After live/dead 
staining and washing steps, cells (~3 million) were incubated with a 
mixture containing optimum concentrations of the Abs together with 
the 2 labeled HBsAg reagents in Brilliant Stain Buffer (BD) for 30 min-
utes on ice (50 μl in V-bottom 96-well plate). Following incubation, 
cells were washed and fixed with 1% formaldehyde before acquisition 
on LSR-Fortessa flow cytometry (BD).
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and the panel of 15 reference genes, as recommended by the manu-
facturer. Only genes that were significantly different (P < 0.05, t test, 
FDR adjusted) and at least 2-fold differentially expressed between 
the 2 groups of patients or 2 cell subsets were considered.
Statistics. Statistical analyses were performed in Prism (Graph-
Pad) using the nonparametric 2-tailed Mann-Whitney U test, the non-
parametric Kruskal-Wallis test followed by Dunn’s multiple compari-
son test, Spearman’s rank correlation, or Wilcoxon’s paired t test as 
stated in the figure legends. P ≤ 0.05 was considered significant.
Study approval. Blood donors were recruited from the viral hepati-
tis clinic at the Royal London Hospital and acute dengue samples from 
Tan Tock Seng Hospital in Singapore. Written informed consent was 
obtained from all subjects. The study was conducted in accordance 
with the Declaration of Helsinki and approved by the Barts and the 
London NHS Trust local ethics review board, the National Research 
Ethics Service Committee London–Research Ethics Committee (ref-
erence 10/H0715/39), and the Singapore National Healthcare Group 
ethical review board (DSRB 2008/00293).
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expressing CD40L) (gift from Mark Connors, NIH/National Institute 
of Allergy and Infectious Diseases [NIAID], Bethesda, Maryland, USA) 
according to a protocol explained in detail previously (Huang et al., ref. 
34). Briefly, irradiated 3T3-msCD40L cells were cultured in U-bottom 
96-well plates to 70% confluency in DMEM medium containing 10% 
FBS. After 1 day, sorted HBsAg-specific B cells were resuspended in 
200 μl IMDM complete medium containing IL-2 (200 U/ml) and IL-21 
(50 ng/ml) and transferred to wells containing feeder cells. For PD-1 
blockade experiments, 5 μg/ml anti–PD-1 (gift of Cheng-I Wang, Sin-
gapore Immunology Network, Singapore, ref. 58) was added into the 
culture medium during the entire experiment. After 13 days, cultured 
cells were washed and resuspended in fresh medium with IL-2, IL-21, 
and IL-6 (50 ng/ml) and then seeded into ELISpot plates.
Functional analysis of AtM compared with naive and classical MBCs 
in vitro. 2,000 Sorted total naive, RM, AM, and AtM B cells were cul-
tured 7 days in 2 steps with CpG polyclonal stimulation, as described 
above. Cell-culture supernatants were collected after both steps and 
tested to measure total IgG concentration using the Human IgG Total 
ELISA kit (eBioscience) according to the manufacturer’s instructions.
ELISpot assays. ELISpot assays for the detection of anti-HBs–pro-
ducing cells were performed on expanded B cells based on a protocol 
by M. Jahnmatz et al. (59) with some modifications. Briefly, ELISpot 
plates (Millipore) were pretreated with 35% ethanol, washed, and 
coated with 1 μg/well (10 μg/ml) r-HBsAg (produced by Gilead Sci-
ences; ref. 54) overnight at 4°C. Plates were washed and blocked; 
then, expanded B cells were added and incubated for 18 hours. IgG 
anti-HBs–secreting B cells were detected by the addition of biotin-
conjugated goat Abs specific for human IgG-Fc (Mabtech, MT78/145), 
then ALP-conjugated streptavidin (BD), followed by development of 
plates using BCIP/NBT (Pierce, catalog 34034) and counting by the 
ImmunoSpot Image Analyzer 3.2 (Cellular Technology).
Anti-HBs ELISA. The MONOLISA anti-HBs Plus Kit (Bio-Rad) 
was used for measuring concentrations of anti-HBs Ab in the serum 
of the healthy vaccinated subjects as well as in culture supernatants 
of sorted specific B cells after expansion in vitro, based on the manu-
facturer’s instructions.
NanoString gene expression analysis. Four different subsets of B 
cells and CD4+ and CD8+ T cell subsets obtained by cell sorting were 
lysed in RTL lysis buffer (QIAGEN, supplemented with 2-mercapto-
ethanol at 1:100) at a ratio of 1 μl RLT to 10,000 cells. Cell lysates 
from a minimum of 10,000 cells were analyzed using the preassem-
bled nCounter GX Human Immunology Kit and the nCounter System 
(NanoString Technologies) according to the manufacturer’s instruc-
tions. Data analysis and heatmap representation were performed 
with nSolver Analysis Software (version 3) provided by NanoString 
Technologies. Expression of 588 different genes was normalized 
based on the geometric means of both the supplied positive controls 
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